NYSE:TEVAPharmaceuticals
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress
Teva Pharmaceutical Industries (NYSE:TEVA) is advancing TEV-408, an anti-IL-15 monoclonal antibody for vitiligo, into a Phase 2b trial following encouraging Phase 1b data.
The Phase 1b study reported improvements in skin pigmentation along with a favorable safety profile, supporting continued development.
The move targets an area where systemic treatment choices for vitiligo remain limited, addressing a clear medical need.
For investors tracking Teva Pharmaceutical Industries, the focus now...